Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 11/2022

12.05.2022 | Original Article

Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens

verfasst von: Wojciech Cytawa, Stefan Kircher, Hubert Kübler, Rudolf A. Werner, Simon Weber, Philipp Hartrampf, Tomasz Bandurski, Piotr Lass, Wojciech Połom, Marcin Matuszewski, Hans-Jürgen Wester, Constantin Lapa, Andreas Rosenwald, Anna Katharina Seitz, Andreas K. Buck

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 11/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this study was to immunohistochemically validate the primary tumor PSMA expression in prostate cancer (PCa) patients imaged with [68Ga]Ga-PSMA PET/CT prior to surgery, with special consideration of PET-negative cases.

Methods

The study included 40 men with newly diagnosed treatment-naïve PCa imaged with [68Ga]Ga-PSMA I&T PET/CT as part of the diagnostic work-up prior to radical prostatectomy. All primary tumors were routinely stained with H&E. In addition, immunohistochemical staining of PSMA was performed and the immunoreactive score (IRS) was computed as semiquantitative measure. Subsequently, imaging findings were correlated to histopathologic results.

Results

Eighty-three percent (33/40) of patients presented focal uptake of [68Ga]Ga-PSMA I&T in the primary tumor in at least one prostate lobe. Among PSMA-PET positive patients, one-third had lymph node metastases (LNM) detected by post-operative histopathology, while in PET negative patients, only 1 out of 7 presented with regional LN involvement; PSMA-avid distant lesions, predominantly in bones, were observed in 15% and 0% of patients, respectively.
The median IRS classification of PSMA expression in tumor tissue was 2 (range, 1–3) both in PSMA-PET positive and negative prostate lobes, with significantly different interquartile range: 2–3 vs. 2–2, respectively (p = 0.03). The median volume of PSMA-PET positive tumors was 5.4 mL (0.2–32.9) as compared to 1.6 mL (0.3–18.3) of PET-negative tumors (p < 0.001). There was a significant but weak correlation between SUVmax and percentage of PSMA-positive tumor cells (r = 0.46, p < 0.001). A total of 35/44 (~80%) lobes were positive in PSMA-PET imaging, when a cut-off percentage of PSMA-positive cells was ≥ 90%, while 19/36 (~53%) lobes with < 90% PSMA-positive cells were PSMA-PET negative.

Conclusion

Positive [68Ga]Ga-PSMA I&T PET/CT scan of primary tumor of PCa results from a combination of factors, such as homogeneity and intensity of PSMA expression, tumor volume and grade, with a cutoff value of ≥ 90% PSMA-positive cells strongly determining PET-positivity. Focal accumulation of [68Ga]Ga-PSMA in the primary tumor may correlate positively with aggressiveness of prostate cancer, harboring higher risk of regional LN involvement and distant metastatic spread.
Literatur
14.
Zurück zum Zitat Murciano-Goroff YR, Wolfsberger LD, Parekh A, et al. Variability in MRI vs. ultrasound measures of prostate volume and its impact on treatment recommendations for favorable-risk prostate cancer patients: a case series. Radiat Oncol. 2014;9:200. https://doi.org/10.1186/1748-717X-9-200 Murciano-Goroff YR, Wolfsberger LD, Parekh A, et al. Variability in MRI vs. ultrasound measures of prostate volume and its impact on treatment recommendations for favorable-risk prostate cancer patients: a case series. Radiat Oncol. 2014;9:200. https://​doi.​org/​10.​1186/​1748-717X-9-200
24.
Zurück zum Zitat Ferraro DA, Rüschoff JH, Muehlematter UJ et al. Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with 68Ga-PSMA-11-PET. Theranostics. 2020; 10: 6082–6094. https://doi.org/10.7150/thno.44584 Ferraro DA, Rüschoff JH, Muehlematter UJ et al. Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with 68Ga-PSMA-11-PET. Theranostics. 2020; 10: 6082–6094. https://​doi.​org/​10.​7150/​thno.​44584
Metadaten
Titel
Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens
verfasst von
Wojciech Cytawa
Stefan Kircher
Hubert Kübler
Rudolf A. Werner
Simon Weber
Philipp Hartrampf
Tomasz Bandurski
Piotr Lass
Wojciech Połom
Marcin Matuszewski
Hans-Jürgen Wester
Constantin Lapa
Andreas Rosenwald
Anna Katharina Seitz
Andreas K. Buck
Publikationsdatum
12.05.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 11/2022
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-022-05831-8

Weitere Artikel der Ausgabe 11/2022

European Journal of Nuclear Medicine and Molecular Imaging 11/2022 Zur Ausgabe